Opens in a new tab

Sibio v Abbott Diabetes Care (CoA, 27 February 2026)

Date27 February 2026
CourtCoA
DivisionLuxembourg (LU)
Type of actionGeneric Order
Case number(s)UPC_CoA_884/2025
Registry referenceUPC-COA-0000884/2025
PartiesSibio Technology Limited v. Abbott Diabetes Care Inc.

Official decision (PDF) · UPC registry entry

Case timeline

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

In an order of 27 February 2026 (UPC_CoA_884/2025), the judge-rapporteur of the UPC Court of Appeal rejected Sibio Technology Limited’s request under Rule 36 for a further exchange of written pleadings in its appeal against the Paris Central Division’s dismissal of its revocation action against Abbott Diabetes Care Inc.’s EP 3 831 283. Sibio relied on the six auxiliary requests maintained by Abbott in its statement of response. The order clarifies the status on appeal of auxiliary requests admitted at first instance and closes the written procedure.

Question

Does a respondent that maintains on appeal auxiliary requests to amend admitted at first instance give the appellant a right to a written reply?

Decision

The auxiliary requests, filed and admitted at first instance, form part of the basis of the appeal under Rules 222.1 and 222.2 unless Abbott withdraws them, and did not need to be refiled (paragraphs 7 to 9). Maintaining them is not a conditional cross-appeal, as Abbott seeks no different outcome from the decision under appeal (paragraph 10). Sibio could have addressed the requests not decided at first instance in its grounds of appeal (paragraph 11), and Abbott had not amended them (paragraph 12). The fact that further pleadings would not disrupt the timetable is not in itself a sufficient reason to allow them (paragraph 13), and refusing them does not breach the right to be heard, since Sibio can respond at the oral hearing (paragraph 14). The written procedure was closed and the oral procedure opened.

Key points for practice

Provisions applied

Rules of Procedure
Rules 35(a), 36, 220.1(a), 222.1, 222.2, 226 and 333.1

Related decisions

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: UPC Court of Appeal.

Dhenne Avocats blog: UPC Appeals: What the Numbers Show.

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CoA_884/2025 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

  1. 27 February 2026 Sibio v Abbott Diabetes Care (CoA, 27 February 2026) Generic Order · UPC_CoA_884/2025
  2. 14 August 2026 Sibio v Abbott Diabetes Care (CoA, 14 August 2026) Appeal · UPC_CoA_884/2025 · appeal, first-instance number cited in the decision

    La cour d'appel rejette l'appel de Sibio : les revendications 1 et 15 du brevet EP 3 831 283 ne contiennent pas d'élément ajouté malgré l'omission de l'étanchéité élastomère, et l'activité inventive n'est pas remise en cause au départ de WO 2011/119896 combiné à US 2008/255440.

What the record states

Nature of the act
Generic Order
Outcome (Dhenne Avocats summary)
La demande de Sibio tendant à des écritures supplémentaires est rejetée : les requêtes subsidiaires d'Abbott admises en première instance font partie de la base de l'appel sans constituer un appel incident, et Sibio pouvait les discuter dans son mémoire d'appel puis à l'audience.
Appeal
Decision of the Court of Appeal.
Instance
Court of Appeal decision.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 3 831 283
Analyte sensor devices, connections, and methods
recorded proprietor: Abbott Diabetes Care Inc
Mentioned in the analysis (role not qualified)
Also mentioned in 8 other decision(s): Sibio v Abbott Diabetes Care (CoA, 14 August 2026) · Sibio Technology v Abbott Diabetes Care (CFI, 21 July 2025) · Abbott Diabetes Care v Sibio Technology (CFI, UPC_CFI_131/2024, 19 Jun · Abbott Diabetes Care v Sibio (CoA, 14 February 2025) · Abbott Diabetes Care v Powell Gilbert LLP (CoA, 9 January 2025) · Powell Gilbert LLP v Abbott Diabetes Care (CFI, 29 July 2024) · Abbott Diabetes Care v Sibio Technology (CoA, 26 July 2024) · Abbott Diabetes Care v Sibio Technology (CFI, UPC_CFI_130/2024, 19 Jun
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.